1. Home
  2. ARWR vs PHIN Comparison

ARWR vs PHIN Comparison

Compare ARWR & PHIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARWR
  • PHIN
  • Stock Information
  • Founded
  • ARWR 2003
  • PHIN 2023
  • Country
  • ARWR United States
  • PHIN United States
  • Employees
  • ARWR N/A
  • PHIN N/A
  • Industry
  • ARWR Biotechnology: Pharmaceutical Preparations
  • PHIN
  • Sector
  • ARWR Health Care
  • PHIN
  • Exchange
  • ARWR Nasdaq
  • PHIN Nasdaq
  • Market Cap
  • ARWR 2.5B
  • PHIN 2.0B
  • IPO Year
  • ARWR 1993
  • PHIN N/A
  • Fundamental
  • Price
  • ARWR $22.03
  • PHIN $58.46
  • Analyst Decision
  • ARWR Buy
  • PHIN Buy
  • Analyst Count
  • ARWR 8
  • PHIN 5
  • Target Price
  • ARWR $43.14
  • PHIN $54.60
  • AVG Volume (30 Days)
  • ARWR 2.5M
  • PHIN 391.5K
  • Earning Date
  • ARWR 08-07-2025
  • PHIN 07-24-2025
  • Dividend Yield
  • ARWR N/A
  • PHIN 1.84%
  • EPS Growth
  • ARWR N/A
  • PHIN 59.07
  • EPS
  • ARWR N/A
  • PHIN 2.56
  • Revenue
  • ARWR $572,976,000.00
  • PHIN $3,358,000,000.00
  • Revenue This Year
  • ARWR $22,306.37
  • PHIN $1.82
  • Revenue Next Year
  • ARWR N/A
  • PHIN $2.34
  • P/E Ratio
  • ARWR N/A
  • PHIN $23.01
  • Revenue Growth
  • ARWR 2816.20
  • PHIN N/A
  • 52 Week Low
  • ARWR $9.57
  • PHIN $36.25
  • 52 Week High
  • ARWR $27.34
  • PHIN $59.60
  • Technical
  • Relative Strength Index (RSI)
  • ARWR 68.08
  • PHIN 73.39
  • Support Level
  • ARWR $20.45
  • PHIN $48.94
  • Resistance Level
  • ARWR $22.75
  • PHIN $59.60
  • Average True Range (ATR)
  • ARWR 1.05
  • PHIN 1.19
  • MACD
  • ARWR 0.26
  • PHIN 0.14
  • Stochastic Oscillator
  • ARWR 86.98
  • PHIN 82.63

About ARWR Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

About PHIN PHINIA Inc.

Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, the company generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.

Share on Social Networks: